Table 1.
Anti-HBsAg and anti-HBeAg effects of compounds 3a–j in HepG2 2.2.15 cell line.
| MNTC b (in µM or µg/mL) | HBsAg inhibition (%) | HBeAg inhibition (%) | |
|---|---|---|---|
| 3a | 7.4 (6.25) | 10.7 | 19.2 |
| 3b | 14.5 (12.5) | 10.0 | 34.1 |
| 3c | 14.5 (12.5) | 0 | 11.4 |
| 3d | 28.5 (25) | 11.8 | 14.8 |
| 3e | 14.1 (12.5) | 0 | 44.4 |
| 3f | 28.9 (25) | 0 | 3.0 |
| 3g | 13.7 (12.5) | 0 | 47.0 |
| 3h | 14.2 (12.5) | 5.0 | 25.8 |
| 3i | 13.5 (12.5) | 0 | 26.0 |
| 3j | 14.1 (12.5) | 0 | 40.2 |
| Docetaxel | 7.7 (6.25) | 0 | 8.2 |
| Paclitaxel | 7.3 (6.25) | 0 | 5.3 |
| 3TC a | 873.4 (200) | 10.9 | 12.5 |
a Positive control (3TC = Lamivudine); b Maximum non-toxic concentration. Cell damage was assessed by means of the MTT assay; cell growth inhibition ≥25% was considered as cytotoxic.